Cross-Sector entity
AARP Illinois is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 17-day window averages about 0.8 stories each week. pharma accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder.
2 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AARP Illinois is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 17-day window averages about 0.8 stories each week. pharma accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 2.5 original sources each. PhRMA appears in 2 tracked Cross-Sector stories published from March 9, 2026 through March 25, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PhRMA. Shared-story counts are live from our verified record — not editorial picks.
Potential Implementation
Earliest projected date for the establishment of the Affordability Board if signed into law.
Senate Review
If passed by the House, the bill will move to the Illinois State Senate for consideration.
House Floor Vote
Expected debate and vote by the full Illinois House of Representatives.
Committee Approval
HB 4472 clears the House Human Services Committee, moving to the full House floor.
The Illinois House Human Services Committee has approved a bill to establish a Prescription Drug Affordability Board with the power to cap high-cost medication prices. This legislative milestone signals a growing state-level movement to regulate pharmaceutical pricing independently of federal efforts.
The debate over Direct-to-Consumer (DTC) pharmaceutical advertising is intensifying as U.S. regulators face mounting pressure to align with global standards. With the U.S. remaining one of only two nations allowing the practice, new legal and ethical challenges are questioning the impact of multi-billion dollar marketing budgets on drug pricing and patient safety.
Source: willitsnews.com · pressdemocrat.com
